• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Sept. 12

Aurobindo Pharma Ltd has announced that it has obtained the approval of the US Food and Drug Administration (USFDA) for Citalopram oral solution 10mg/5ml. The company already has USFDA approval for Citalopram of 10, 20 and 40 mg strengths in tablet form. Citalopram is indicated in the treatment of depressive disorders. In a press release here on Tuesday, the company said the latest approval opens on opportunity of over $4-million market additionally to it. The latest approval takes the total USFDA approved products of Aurobindo to 30, inclusive of tentative approvals, the release said.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hyundai to set up R&D centre in Chennai

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line